Raising awareness of covert killer: pulmonary fibrosis

August 12, 2014 by Campbell North, Pittsburgh Post-Gazette

Despite claiming an estimated 40,000 lives annually - roughly the same number as breast cancer or prostate cancer - pulmonary fibrosis remains one of the least known covert killers in the country.

"Survivors of come together in droves to raise awareness," said Teresa Barnes, vice president of patient outreach and program support for the Coalition for Pulmonary Fibrosis, based in Culver City, Calif. "Pulmonary fibrosis leaves no survivors," except a relative handful who receive .

,Pulmonary fibrosis causes progressive lung scarring and eventually suffocation.

Hope is on the horizon. The first treatment options available, InterMune's pirfenidone and Boehringer Ingelheim's nintedanib, are being evaluated by the Food and Drug Administration and may become available as early as this fall.

The disease has an annual fundraising walk/run in the summer in Pittsburgh organized by Tami Rippy, whose mother died of the disease in March 2009. "Knowing she was suffering, and literally suffocating, that there was no treatment, no idea where it came from or why it happened makes it devastating," said Rippy. "People assume my mom got it because she did this or that or smoked, but she was healthy all these years."

The terminal diagnosis often disguises itself in generic symptoms, such as dry cough and fatigue. It typically affects people over 50 but does not discriminate, debilitating runners and smokers alike. The overwhelming majority of cases are idiopathic, meaning no known cause is ever identified and the condition is known as idiopathic or IPF.

According to the coalition, pulmonary fibrosis patients may have an exaggerated or uncontrolled healing response that, over time, produces excessive fibrous scar tissue - or fibrosis - in the lungs. It's not known what sets this abnormal tissue-repair process in motion.

"This is worse than a cancer diagnosis," said Kevin Gibson, clinical director of a center at the University of Pittsburgh Medical center that specializes in lung disease. "With cancer you're offered treatment, but with IPF there is no treatment apart from transplant." Fewer than 1 percent of these patients receive them.

The two drugs are considered breakthrough therapies, meaning the FDA will expedite the process of their development and review. The drugs work by trying to reduce the onset and progression of the disorder, which also destroys blood vessels, diminishing the ability to circulate oxygen in the body.

"If they're approved it's great, but the treatment's effects are modest at best," said Dr. Gibson. "It is still a long way until a cure."

Although the condition has been recognized for the past century, relatively little is known about pulmonary fibrosis, the "disease course being highly variable and unpredictable," he said.

Despite being five times as prevalent as , which receives about $85 million in federal funding annually, the condition receives only $18 million a year, according to the Coalition for Pulmonary Fibrosis.

Explore further: Protein molecule may improve survival in deadly lung disease

Related Stories

Protein molecule may improve survival in deadly lung disease

May 6, 2014
Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to ...

Registry for fatal lung disease aims to speed improvements in care

June 5, 2014
Duke Clinical Research Institute (DCRI) has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis.

Two drugs offer hope for fatal lung disease

May 18, 2014
(HealthDay)—A pair of drugs offers new hope to patients with a progressive, fatal disease that robs their breath by scarring the lungs, according to clinical trial results.

Cough may warn of danger for patients with lung-scarring disease

October 18, 2011
A new analysis has found that coughing may signal trouble for patients with the lung-scarring disease known as idiopathic pulmonary fibrosis. The study, published in the journal Respirology, found that patients with the condition ...

'Beneficial inflammation' may promote healing in pulmonary fibrosis

April 25, 2014
Inflammation has long been considered an integral part of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis. New research at National Jewish Health, however, suggests that a little inflammation ...

Recommended for you

Flu infection study increases understanding of natural immunity

January 23, 2018
People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according ...

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.